LightOx

LightOx is a biotechnology company headquartered in Newcastle upon Tyne, UK, that specializes in the design and development of light-activated small molecule therapeutics. The company has engineered a platform technology that utilizes patented, fluorescent drug-like compounds which remain inert until activated by specific wavelengths of light. This mechanism enables precise, localized treatment, allowing the drug to preferentially target and induce apoptosis in diseased cells while minimizing damage to surrounding healthy tissue. Their research spans various applications, including oncology, dermatology, and microbial control. In addition to their therapeutic pipeline, the company develops and sells research tools, including imaging probes, through partnerships such as their agreement with Merck.

The company's primary focus is the treatment of early-stage oral cancer and pre-cancerous lesions. Their lead candidate, LXD191, is a topical, gel-based formulation designed for simple application in a clinical setting, aimed at offering a less invasive alternative to traditional surgery. Having successfully completed pre-clinical testing, LightOx is preparing to initiate Phase I/II clinical trials for LXD191 in 2025. Furthermore, the company is expanding its therapeutic reach with projects like LXD231, an antimicrobial candidate intended to treat chronic wound infections. Spun out of Durham University in 2016, LightOx maintains a portfolio of global patents and collaborates with international academic and clinical institutions to advance its pipeline toward clinical application.